Cue Biopharma Q3 net loss $0.07/sh; ImmunoScape deal $15M upfront; new CEO

Cue Biopharma, Inc.

2025-Q3 EPS reported -$0.31 revenue$5,524,000

Q3 net loss $7.45M ($0.07 EPS); revenue $2.15M (down 36% YoY); cash $11.7M (down 48% from Dec 2024).
Collaboration with ImmunoScape: upfront total $15M ($10M in Q4 2025, $5M in Nov 2026) plus 40% equity stake.
Usman Azam appointed President & CEO effective Sep 29; leadership transition to advance autoimmune asset CUE-401.
CUE-101+pembrolizumab in HPV+ HNSCC: 50% ORR, 88% 12-month OS, median OS 32.7 months.
R&D spend $4.8M (down 49% YoY); G&A $4.9M (up 72% YoY) due to severance and professional fees.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.